Reviews/Osteoporosis Fracture Prevention/Bisphosphonate atypical femoral fracture
Bisphosphonate Safety · ostfrac_03 · v2
Seven large groups of patients across the US, Sweden, Canada, Spain, Korea and Denmark were examined, and all show that the longer someone takes bisphosphonates, the higher their risk of an atypical femur fracture [1][2][3][4][5][6][7][9]. Several studies confirmed the fractures by having radiologists review the x-rays rather than relying on billing codes [1][2][3][4][6][9]. When patients stop the drug, the added risk falls away quickly [1][3]. The panel treated this as a settled direction because the same duration-linked pattern repeats in independent populations and health systems. The main caveats are that all the evidence is observational, so the exact size of the effect is harder to pin down, and that atypical fractures also happen in people who never took the drug [2].
Multiple independent cohorts and case-control studies demonstrate that atypical femur fracture risk rises with duration of bisphosphonate exposure. In the Kaiser cohort the hazard ratio rose from 8.86 at 3 to less than 5 years to 43.51 at 8 years or more [1], and in the Danish case-cohort 5 to 7 years of use carried an adjusted HR of 7.29 [2]. Incidence climbed from 1.78 to 113.1 per 100,000 per year across increasing exposure in one Kaiser population [4] and was validated with a >20-fold rise in a second [6]. Case-control estimates concur: OR 2.74 at 5 years or longer [5], OR 9.46 beyond 3 years with p for trend 0.01 [7], and OR 25.65 for BP use [9]. The risk fell by 70% per year after withdrawal [3], and an adherence-graded signal reached HR 4.06 in year five even without radiographic adjudication [8]. The contested point: The direction is not in dispute; what the evidence cannot settle is causal magnitude, since every study is observational and bisphosphonate users are selected for low bone mass and high fracture risk. The multifactorial nature of the outcome is explicit in the corpus: Bauer reports that 31% of those with AFF had no BP exposure [2].
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All included evidence is observational; confounding by indication (BP users are selected for low bone mass and high fracture risk) means the causal magnitude is uncertain even though the direction is consistent.
AFF is multifactorial, not BP-dependent: Bauer [2] reports roughly 31% of AFF cases had no bisphosphonate exposure, so any inference stronger than a risk-increase (e.g. that BP is necessary/causal) would overreach the claim's wording.
Where it remains uncertain. All evidence is observational and about a third of atypical fractures occur in people with no bisphosphonate exposure [2], which bounds the causal magnitude but not the direction.
Aleatory
AFF is very rare even among long-term users, with absolute increases on the order of 5 cases per 10,000 patient-years [3], so individual-level occurrence carries large irreducible chance.
Epistemic
Every included study is observational; no trial randomises bisphosphonate exposure, so confounding by indication cannot be excluded.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest adjudicated cohort; establishes a steep duration-response relationship.
“the risk of atypical fracture increased with longer duration of bisphosphonate use: the hazard ratio as compared with less than 3 months increased from 8.86 (95% confidence interval [CI], 2.79 to 28.20) for 3 years to less than 5 years to 43.51 (95% CI, 13.70 to 138.15) for 8 years or more.”
Panel auditInternal validity: high · scope of inference: Women aged 50+ receiving bisphosphonates in a US integrated health system, 2007-2017.Key limitations: observational, not randomised · health-system population · EHR-derived exposure
Independent Danish case-cohort with blinded review confirming duration-response and reversibility.
“Compared to <1 year of BP use, 5 to 7 years of use was associated with a 7-fold increase in AFF (adjusted HR = 7.29 [CI: 3.07, 17.30]); the risk of AFF fell quickly after discontinuation.”
Panel auditInternal validity: high · scope of inference: Danish adults aged 50+ with subtrochanteric/shaft fractures, 2010-2015.Key limitations: observational · nearly one-third of AFF had no BP exposure
Swedish nationwide data quantifying dose-dependent risk and 70%/yr decline after withdrawal.
“The duration of use influenced the risk (odds ratio per 100 daily doses, 1.3; 95% CI, 1.1 to 1.6).”
Panel auditInternal validity: high · scope of inference: Swedish women aged 55+ with femoral fracture in 2008.Key limitations: small absolute risk · observational
Spanish primary-care data with a significant duration trend.
“The risk increased with long-term use, with an OR of 9.46 (2.17 to 41.3) comparing those using bisphosphonates over 3 years versus no users (p for trend=0.01).”
Panel auditInternal validity: medium · scope of inference: Spanish women aged 65+ in a low fracture-risk primary-care population, 2005-2008.Key limitations: small sample · wide CIs · database-defined fractures
4 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Reproducible duration-response across multiple independent adjudicated cohorts firmly supports the directional claim, with residual uncertainty confined to the observational design rather than the direction.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Unmeasured confounding by indication. Because users are selected for low bone mass and high fracture risk, the observational estimates [1][5][7] may overstate the drug-specific effect. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Active-comparator new-user designs (e.g. bisphosphonate versus another osteoporosis therapy) with high-dimensional propensity adjustment to isolate the exposure effect.
Open question: How much of the duration-risk association is causal versus driven by confounding by indication? Why it is still open: Every corpus study is observational and users are selected for high fracture risk [1][5], so the drug-specific component cannot be separated from the indication.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19